To recover your password please fill in your email address
Please fill in below form to create an account with us
A randomised phase III trial testing the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) in men having radiation therapy for localised prostate cancer at very high risk of recurrence (ANZUP1801).
See ANZCTR for full trial details >
|
Trial Summary: |
To determine the effectiveness of darolutamide as part ofadjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high risk of recurrence. |
|
Supported By: |
Bayer |
|
Eligibility: |
Adults with very high risk localised or locally advanced prostate cancer. |
|
Registration ID: |
NCT04136353 |
|
Participation: |
International |
|
Australian Lead Group: |
ANZUP |
|
Status: |
Open |
|
Activation Date: |
31 March 2020 |
|
Chairs: |
Prof Christopher Sweeney and Dr Tamim Niazi |
|
Contact: |